• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Full cost of diagnostic pathology for lung carcinoma in Italy: results from four Pathology Units.意大利肺癌诊断病理学的全成本：来自四个病理学科室的结果。
Pathologica. 2023 Apr;115(2):83-89. doi: 10.32074/1591-951X-837. Epub 2023 Feb 14.
2
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study.非小细胞肺癌预测性分子病理学中的下一代诊断算法：KWAY 意大利多中心成本评估研究。
Crit Rev Oncol Hematol. 2022 Jan;169:103525. doi: 10.1016/j.critrevonc.2021.103525. Epub 2021 Nov 20.
3
Lobectomy for early-stage lung carcinoma: a cost analysis of full thoracoscopy versus posterolateral thoracotomy.肺叶切除术治疗早期肺癌：全胸腔镜与后外侧开胸术的成本分析。
Surg Endosc. 2012 Feb;26(2):431-7. doi: 10.1007/s00464-011-1891-y. Epub 2011 Sep 5.
4
Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy.意大利关于使用正电子发射断层扫描对孤立性肺结节进行检查以及对非小细胞肺癌患者进行分期的经济学分析。
Q J Nucl Med Mol Imaging. 2004 Mar;48(1):49-61.
5
Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.非小细胞肺癌（NSCLC）患者的经济负担：LIFE研究
J Cancer Res Clin Oncol. 2017 May;143(5):783-791. doi: 10.1007/s00432-016-2326-x. Epub 2017 Feb 18.
6
[Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].[卫生技术评估报告：用于宫颈癌筛查的计算机辅助巴氏试验]
Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 3):e1-43.
7
Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications.采用现行和近期分类标准的非小细胞肺癌的病理学家间诊断一致性。
Arch Pathol Lab Med. 2018 Dec;142(12):1537-1548. doi: 10.5858/arpa.2017-0481-OA. Epub 2018 Apr 30.
8
Costs of non-small cell lung cancer in the Netherlands.荷兰非小细胞肺癌的成本。
Lung Cancer. 2016 Jan;91:79-88. doi: 10.1016/j.lungcan.2015.10.015. Epub 2015 Oct 17.
9
Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.对葡萄牙而言，针对两项治疗晚期非小细胞肺癌的III期试验中的五种双联化疗方案进行成本最小化分析。
Lung Cancer. 2006 Jun;52(3):365-71. doi: 10.1016/j.lungcan.2006.03.005. Epub 2006 May 2.
10
Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience.非小细胞肺癌中表皮生长因子受体突变和间变性淋巴瘤激酶重排的通用检测与局部晚期和仅晚期分子检测的临床及成本影响：一所三级学术机构的经验
Arch Pathol Lab Med. 2016 Apr;140(4):358-61. doi: 10.5858/arpa.2015-0147-OA.

引用本文的文献

1
Economic assessment of NGS testing workflow for NSCLC in a healthcare setting.医疗环境中用于非小细胞肺癌的二代测序检测工作流程的经济评估。
Heliyon. 2024 Apr 5;10(7):e29272. doi: 10.1016/j.heliyon.2024.e29272. eCollection 2024 Apr 15.

本文引用的文献

1
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee.肺癌免疫治疗的预测生物标志物：国际肺癌研究协会病理学委员会的观点。
J Thorac Oncol. 2022 Dec;17(12):1335-1354. doi: 10.1016/j.jtho.2022.09.109. Epub 2022 Sep 29.
2
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study.非小细胞肺癌预测性分子病理学中的下一代诊断算法：KWAY 意大利多中心成本评估研究。
Crit Rev Oncol Hematol. 2022 Jan;169:103525. doi: 10.1016/j.critrevonc.2021.103525. Epub 2021 Nov 20.
3
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.2021 年世卫组织肺肿瘤分类：自 2015 年以来的进展影响。
J Thorac Oncol. 2022 Mar;17(3):362-387. doi: 10.1016/j.jtho.2021.11.003. Epub 2021 Nov 20.
4
The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization.病理学家在肿瘤分子特征新一代时代中的作用。
Diagnostics (Basel). 2021 Feb 18;11(2):339. doi: 10.3390/diagnostics11020339.
5
Lung Cancer in Italy.意大利的肺癌
J Thorac Oncol. 2019 Dec;14(12):2046-2052. doi: 10.1016/j.jtho.2019.05.019.
6
Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non-Small-cell Lung Cancer: Clinical and Budget Effect.检测间变性淋巴瘤激酶阳性非小细胞肺癌的 Ventana ALK (D5F3)：临床和预算效果。
Clin Lung Cancer. 2018 Sep;19(5):e735-e743. doi: 10.1016/j.cllc.2018.05.012. Epub 2018 May 31.
7
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.美国病理学家学会、国际肺癌研究协会和分子病理学会更新的肺癌患者靶向酪氨酸激酶抑制剂治疗选择的分子检测指南。
J Thorac Oncol. 2018 Mar;13(3):323-358. doi: 10.1016/j.jtho.2017.12.001. Epub 2018 Jan 25.

意大利肺癌诊断病理学的全成本：来自四个病理学科室的结果。

Full cost of diagnostic pathology for lung carcinoma in Italy: results from four Pathology Units.

机构信息

Studio di Economia Sanitaria, Milan, Italy.

School of Pharmacology, Biology and Biotechnologies Department "Lazzaro Spallanzani", University of Pavia, Pavia, Italy.

出版信息

Pathologica. 2023 Apr;115(2):83-89. doi: 10.32074/1591-951X-837. Epub 2023 Feb 14.

DOI:10.32074/1591-951X-837
PMID:36790110
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10463002/
Abstract

OBJECTIVE

To calculate the full cost of diagnostic pathology tests for Non-Small Cell Lung Cancer (NSCLC) across four Italian Pathology Units.

METHODS

Pathology Units were located in private (2) and public (2) hospitals distributed across the Italian territory (North: 2; Centre: 1; South: 1). Pathologists provided via questionnaire data on tests on NSCLC samples along with the identification and quantification of the necessary healthcare resources (diagnostic technologies, laboratory instruments and personnel). Resources were valued according to hospital-specific unit, yearly and hourly costs (disposables; technologies; professional clusters).

RESULTS

The full cost per NSCLC tissue sample included histopathological immunophenotypic and required molecular analysis. Overall, it reached € 659.77 and it was mainly composed of direct costs (77.69%). The processing of a NSCLC tissue sample was labour intensive, as a relevant share of the full cost (44.98%) was actually due to personnel costs, with laboratory technicians, biologists and pathologist driving this finding (17.09%,12.43% and 10.81%, respectively).

CONCLUSIONS

The results of this research can facilitate the negotiation of new dedicated tariffs for NSCLC sample processing with the national or local third party-payers.

摘要

目的

计算意大利四个病理科单位非小细胞肺癌（NSCLC）诊断病理学检测的全成本。

方法

病理科单位位于意大利各地的私立（2 家）和公立医院（2 家）。病理学家通过问卷提供 NSCLC 样本检测以及必要医疗资源（诊断技术、实验室仪器和人员）的识别和量化数据。根据医院特定的单元、年度和小时成本（消耗品；技术；专业集群）来评估资源。

结果

每例 NSCLC 组织样本的全成本包括组织病理学免疫表型和所需的分子分析。总体而言，达到 659.77 欧元，主要由直接成本（77.69%）构成。处理 NSCLC 组织样本需要大量的人力，因为全成本的一个重要部分（44.98%）实际上是人员成本，其中实验室技术人员、生物学家和病理学家占比最大（分别为 17.09%、12.43%和 10.81%）。

结论

这项研究的结果可以促进与国家或地方第三方付款人就 NSCLC 样本处理达成新的专用定价。